^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Adenocarcinoma

    Related cancers:
    1d
    NeoART: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=36, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Suspended --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • oxaliplatin
    3d
    PHOX: Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=99, Recruiting, Mayo Clinic | Trial completion date: May 2031 --> May 2027 | Trial primary completion date: May 2031 --> May 2027
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • docetaxel • oxaliplatin • leucovorin calcium • fluorouracil topical
    4d
    CGVV858A12101: Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors (2025-521911-38-00)
    P1/2, N=26, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • letrozole • goserelin acetate • leuprolide acetate for depot suspension
    4d
    PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation. (PubMed, Br J Cancer)
    PD-L1 CPS is shaped by clinicopathological context and biopsy site. The persistently lower CPS ≥ 5 prevalence at SBH despite validated testing highlights assay variability and reinforces the urgent need for assay standardisation. Preferential use of primary tumor tissue may help reduce metastasis-specific bias.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    5d
    Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysis. (PubMed, Future Oncol)
    Anti-CLDN18.2 therapy, primarily consisting of first-line zolbetuximab combined with chemotherapy, significantly improved progression-free survival (PFS) (hazard ratios [HR] 0.564; 95% confidence interval [CI]: 0.417-0.711) and overall survival (OS) (HR 0.716; 95% CI: 0.631-0.802), along with enhanced 1- and 2-year survival rates...Standardized definitions for CLDN18.2 positivity and high expression are urgently needed. www.crd.york.ac.uk/prospero identifier is CRD420251123719.
    Retrospective data • Review • Journal
    |
    CLDN18 (Claudin 18)
    |
    Vyloy (zolbetuximab-clzb)
    6d
    SOS6C: Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=300, Enrolling by invitation, Mayo Clinic | Trial primary completion date: Oct 2028 --> Jul 2030 | Trial completion date: Oct 2028 --> Jul 2030
    Trial completion date • Trial primary completion date • Grant
    6d
    Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial (clinicaltrials.gov)
    P=N/A, N=1010, Not yet recruiting, Mayo Clinic | Trial completion date: Oct 2027 --> Jul 2030 | Initiation date: Mar 2026 --> Jun 2026 | Trial primary completion date: Oct 2026 --> Jul 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    6d
    PSI-Immune: Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (clinicaltrials.gov)
    P2, N=880, Recruiting, Diwakar Davar | N=480 --> 880
    Enrollment change
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    7d
    A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 expression
    7d
    A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab)
    7d
    Cryotherapy for Locally Advanced Esophageal Cancer (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Hunter Holmes Mcguire Veteran Affairs Medical Center | Trial completion date: Jul 2025 --> Jul 2026
    Trial completion date
    8d
    Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer (clinicaltrials.gov)
    P=N/A, N=15, Completed, Hunter Holmes Mcguire Veteran Affairs Medical Center | Unknown status --> Completed
    Trial completion